Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib + PD-1 Inhibitors in ES-SCLC
NCT07110103Phase 2
Key facts
- Status
- Recruiting
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Countries
- 1
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Small Molecules
- Drugs
- golidocitinib
- Conditions
- small cell lung cancer (SCLC)
01
Overview
Phase 2, open-label, single-arm trial of golidocitinib in small cell lung cancer (SCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 2 years. Started Oct 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
golidocitinib with PD-1 inhibitors
Induction with PD-1 inhibitors + chemo, followed by maintenance with golidocitinib + PD-1 inhibitors
03
Who it enrols
Adults with previously untreated extensive-stage small cell lung cancer, ECOG 0-1, adequate organ function, and no active autoimmune or infectious diseases.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Overall Survival
Safety and Tolerability
Beyond the preview
Go deeper on NCT07110103.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110103.